This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $309.86 in the latest trading session, marking a -0.68% move from the prior day.
Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $288.75, marking a +1.95% move from the previous day.
Moderna (MRNA) Reports 2023 Business View & Pipeline Updates
by Zacks Equity Research
Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $286.02, moving -0.96% from the previous trading session.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $287.32 in the latest trading session, marking a -0.82% move from the prior day.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $290.55 in the latest trading session, marking a -0.91% move from the prior day.
Entrada (TRDA) Down on Regulatory Update for DMD Candidate
by Zacks Equity Research
Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
by Zacks Equity Research
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
by Kinjel Shah
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Vertex Pharmaceuticals (VRTX) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.40, marking a -1.18% move from the previous day.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $312.09 in the latest trading session, marking a +1.63% move from the prior day.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
by Zacks Equity Research
bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.
Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy
by Zacks Equity Research
Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.
3 Non-Energy S&P 500 Stocks With Enough Energy to Boost Returns
by Kinjel Shah
Though energy companies have been among the best-performing stocks in the S&P 500 index, here we discuss some top-performing non-energy S&P 500 stocks like MRK, VRTX and MCK.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
by Zacks Equity Research
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
3 Reasons Growth Investors Will Love Vertex (VRTX)
by Zacks Equity Research
Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
Esperion (ESPR) Reports Positive Data From CLEAR Study
by Zacks Equity Research
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Vertex (VRTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $317.58, marking a +1.85% move from the previous day.
Centene (CNC) Invests Nearly $8M to Build Texas Community Center
by Zacks Equity Research
Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state.